The evaluation of diagnostic performance of some enzymes for diagnosis and detection of breast cancer by ROC curve

Yıl 2016, Cilt: 3 Sayı: 6, 250 - 4, 15.06.2016

Halit Demir , Sıddık Keskin , Canan Demir Halis Gokyer

https://doi.org/10.17546/msd.43631

Cited By: 1

Öz

Objective: In this study, it was aimed to examine the performance of Arylesterase (ARE), Paraoxonase-1 (PON-1) and Adenosine deaminase (ADA) enzymes to identify cancer patients and their stages with ROC curve in serum samples taken from patients diagnosed as breast cancer in the Medical Oncology services at Yüzüncü Yıl University.

Material and Methods: The 25 healthy controls and 25 breast cancer patients are included in this study. 8 patients are in stage-1, 9 patients are in stage-2 and 8 patients are in stage-3. Adenosine deaminase (ADA), Paraoxonase-1 (PON-1) and Arylesterase (ARE) activities were detected in serums with Spectrophotometric method. Descriptive statistics for the traits studied were presented as median, mean, standard deviation, minimum and maximum value. In terms of these traits, Kruskal-Wallis test was performed to find out whether there are no differences between stages and control group. In addition, ROC analysis was performed to evaluate the performances of enzymes to classify patient and control group.

Results: The differences between stage-1, stage-2, stage-3 and control group for Adenosine deaminase (ADA) enzyme activities were found statistically significant (p<0.01). Besides, the difference between stage-2 and stage-3 was found insignificant for Paraoxonase-1 (PON-1) and Arylesterase (ARE) enzyme activity. Last, the difference between them and stage-1 and control group was found statistically significant.

Conclusion: It can be inferred that sensitivity and specificity values of the enzymes are favorable high and they have outstanding performance to identify tumor stage as well as patient and control group. Therefore, these enzymes should be suggested as a “diagnostic test” to classify patients with breast cancer and control group.

Anahtar Kelimeler

Arylesterase, Adenosine deaminase; Sensitivity; Specificity

The evaluation of diagnostic performance of some enzymes for diagnosis and detection of breast cancer by ROC curve

Öz

Kaynakça

• Greenlee RT, Murray T, Bolden S. Cancer Statistics. Cancer J Clin. 2000; 50: 7-33.
• Ayhan F, Yorgancıoğlu R. Meme Kanseri ve Rehabilitasyon. Türkiye Klinikleri J Int Med Sci. 2006. 2: 39–48.
• Saip, P., Keskin, S., Özkan, M., Kaplan, M.A., Aydoğan, F., Demirağ, G.G., Uzunoğlu, S., Engin, H., Başaran, G., Güler, N., Uygun, K., Demirkan, B.,Özdemir, F., Çubukçu, E., Salepçi, T., Çiçin, İ. Türkiye’de Meme Kanserli Hastaların Tanı ve Tedavi Yöntemlerine Ulaşım Hızı; Çok Merkezli Gözlemsel Çalışma. Meme Sağlığı Dergisi. 2011; 7:2.
• Meram İ, Sibel A, Tarakçıoğlu M. Kanserde Serum Arginaz Aktivitesi. Van Tıp Dergisi. 2000;7 (1): 20-23.
• Kumaraguruparan R, Subapriya R, Kabalimoorthy J and Nagini S. Antioxidant profile in the circulation of patients with fibroadenoma and adenocarcinoma of the breast. Clin. Biochem. 2002; 35: 275-279.
• Gökyer H. Meme Kanserli Hastalarda Adenozin Deaminaz, Aril Esteraz ve Paraoksanaz-1 Serum Aktivitelerinin İncelenmesi (Yüksek Lisans Tezi). YYÜ, Fen Bilimleri Enstitüsü. 2015. Van.
• Durrington PN, Mackness B, Mackness MI. Paraoxonase and Atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21 (4): 473-80.
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. 2008, 2010. Available from:URL:http://globocan.iarc.fr.
• Gülçin I. Isırgan Otunun (Urtica dioica) Antioksidant Aktivitesinin Belirlenmesi, Oksidatif Enzimlerin Karakterizasyonu ve Bazı In vivo Etkilerinin İncelenmesi (doktora tezi). A.Ü, Fen Bilimleri Enstitüsü. 2002. Erzurum.
• Balcı H, Genç H, Papila C, Can G, Papila B, Yanardağ H, Uzun H. Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, andcolorectalcancer. J.Clin.LabAnal. 2012; 26 (3): 155–60.
• Al-Rubaye F, Morad T. Serum adenosine deaminase activity in Iraqi patients with breast cancer on tamoxifen therapy. Gaziantep Med J. 2012; 18 (3): 139-142.
• Bobin-Dubigeon C, Lefrançois A, Classe JM, Joalland MP, Bard JM. Paired measurement of serum amyloid A (SAA) and paraoxonase 1 (PON1) as useful markers in breast cancer recurrence.Clin.Biochem.2015;48(16-17):1181-3.